More Troubles For Martin Shkreli – That Guy Drug Makers Despise

Executive Summary

Martin Shkreli, who is largely despised by the biopharmaceutical industry, may be in even deeper trouble than he thought, with prosecutors telling a judge on May 3 they are considering additional charges against the former drug company CEO, who already is facing seven criminal counts, including securities fraud. Turing Pharmaceuticals Inc., one of the firms Shkreli created and used to lead, also is up against a new lawsuit from Impax Laboratories Inc., which is claiming breach of contract involving the drug Daraprim, whose price was hiked by more than 5,000%.